Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
about
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient managementPharmacokinetic and pharmacodynamic profile of bendamustine and its metabolitesTrial Watch: Proteasomal inhibitors for anticancer therapyBortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysisRetrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancyUpdate on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibProspective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideA Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphomaManagement of indolent lymphoma: where are we now and where are we going.From bortezomib to other inhibitors of the proteasome and beyond.Bortezomib for the treatment of non-Hodgkin's lymphomaPhase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cellsThe optimal management of follicular lymphoma: an evolving field.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Bendamustine: role and evidence in lymphoma therapy, an overview.Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateInnovation in non-Hodgkin lymphoma drug discovery: what needs to be done?Low-grade lymphoma: Beyond fludarabine-single therapy.The role of the proteasome in AML.A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.Novel agents in indolent lymphomas.Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.
P2860
Q27002428-07D1DC32-7E1C-4954-B033-C4F35D68ABFCQ27011795-AFD7A98C-9B38-426B-B609-A2657A0D2D41Q28082910-AA72AB7E-EE43-47A3-AB90-94BF9979BBE0Q33402885-D8B56DCD-2B1E-4EA3-89A1-B25EA98C719AQ33410592-D1FD0767-7A58-4BA5-B396-3B81C1C3BDA1Q33416533-F964A7BB-6233-4E0D-BB7D-1EC91DD4D24DQ33417803-4CF39D16-0853-4C61-851D-49E17042AC19Q33419346-01BCD4F1-9E69-494F-8EEA-F810924C69CDQ33424956-1CACA9BB-9BBB-4935-8C01-0C2EEAD79F06Q33439291-6E696C59-273D-44CC-986D-5BF23D081245Q33713106-A0708D7C-7744-4458-9EBF-0DBCE9E9C16DQ33877999-03384B94-A747-4DF9-A450-94CD92C1F70AQ34322781-569B0579-6D2F-4227-886D-D111E46492C6Q35905929-B779D075-8AFB-4B70-B6BB-2B329028E88DQ35956862-56FA5F4F-44B4-4538-9EB5-3063FF28BF7BQ35989980-22175BB7-FAF6-4E16-8CC3-E98BD1E9575BQ36000197-73E52167-7D62-4C26-9629-5FCE440A64E8Q36784860-D42DB18C-D186-4D25-8CA9-2202E5AE13D6Q36852277-D4C2D85B-3833-471C-A0BB-BA19A23D2D68Q36868056-EA2BD246-36E9-43D0-86B2-5526DA376152Q37065959-C1F97002-65A5-4363-AEED-AFD38F190A4BQ37524930-8CE558EE-1C4F-41BA-A68A-CD1DB23A9AAFQ37706483-95D5976F-B26F-448D-82CB-B22DD9E2F3C9Q38124009-8C7E1E9E-4434-48C2-95E2-DB6D3A28D3F1Q38152510-46A9104C-4767-42C8-AA49-29B761440958Q38158084-9BDCECFC-706D-449A-9FA0-81A0499ED2ACQ38171874-6644AF61-4C36-4992-A56D-FECA21ACAB41Q38548134-D5413B1C-667D-49B1-B915-065546B3C795Q38642648-C33CCBDF-53A2-4D39-A397-3C6843502A75Q38939419-C1B6FF96-ACAF-43AA-85CC-84C96CDB16C0Q38941292-C7E3D43B-DB2A-4A61-B817-9B426266A47EQ39027087-B8AEF2AB-D573-4613-863C-A502A4CC7E0CQ39031363-0878F3DD-835E-442B-88BB-5CBF41838EE4Q39091822-0A34DA55-D698-43A8-A67D-6E1ABA4B839DQ39185574-17A41DCB-D0B6-4755-9FB3-F858650B9F1FQ39431412-21DAF6D0-2B0F-44B6-85BB-B3003AF82136Q39627475-5F526EAB-B676-4001-86AB-EA742E2DF2A6Q40015002-EE3BA050-942A-4C6F-B6B0-FC8E14C34296Q40744550-ADEFEC55-666E-491F-8AA5-A5B9D1BAF665Q42132657-27777F22-2076-4C82-B60A-017D2F77DEB8
P2860
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bortezomib, bendamustine, and ...... : the phase II VERTICAL study.
@ast
Bortezomib, bendamustine, and ...... : the phase II VERTICAL study.
@en
type
label
Bortezomib, bendamustine, and ...... : the phase II VERTICAL study.
@ast
Bortezomib, bendamustine, and ...... : the phase II VERTICAL study.
@en
prefLabel
Bortezomib, bendamustine, and ...... : the phase II VERTICAL study.
@ast
Bortezomib, bendamustine, and ...... : the phase II VERTICAL study.
@en
P2093
P356
P1476
Bortezomib, bendamustine, and ...... : the phase II VERTICAL study.
@en
P2093
Alfred Saleh
Amanda F Cashen
Bipinkumar Amin
Brad S Kahl
Bruce D Cheson
Hongliang Shi
Jeffrey Letzer
Jeffrey V Matous
Michael E Williams
Nathan Fowler
P304
P356
10.1200/JCO.2010.32.1844
P407
P577
2011-08-01T00:00:00Z